| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
BAM8-22 targets Mas-related G-protein-coupled receptors (MRGPRs), specifically SNSR3 and SNSR4 (also known as MrgprC11 and hMrgprX1). It acts as a potent agonist at these receptors with EC50 values of 28 nM and 14 nM for SNSR3 and SNSR4, respectively. It also interacts with NMDA receptors to produce spinal analgesic effects.
|
|---|---|
| ln Vitro |
BAM8-22 potently activates SNSR3 and SNSR4 with low nanomolar EC50 values. It displays no affinity for opioid receptors compared to the full-length BAM22 peptide. The peptide has been shown to inhibit microglia activation by repressing CX3CR1 expression via upregulating miR-184.
|
| ln Vivo |
In vivo, BAM8-22 produces itch and nociceptive sensations in humans independent of histamine release. It induces scratching in mice in an Mrgpr-dependent manner. The peptide exhibits spinal analgesic effects through interaction with NMDA receptors.
|
| Enzyme Assay |
In vitro receptor binding assays typically measure the displacement of a radiolabeled ligand from SNSR/MRGPR receptors expressed in cell membranes. BAM8-22 is incubated with membrane preparations and a radioactive tracer, and the IC50 or Ki is determined. Functional assays measure receptor activation using calcium flux or GTPγS binding in cells expressing SNSR3 or SNSR4.
|
| Cell Assay |
In vitro cellular assays evaluate the activity of BAM8-22 on cells expressing MRGPRs. Calcium mobilization assays are commonly used, where receptor activation by BAM8-22 is detected using a fluorescent calcium indicator. The EC50 for receptor activation is determined from dose-response curves. The peptide's effects on microglia activation and CX3CR1 expression can also be assessed in cell culture.
|
| Animal Protocol |
In vivo animal experiments are conducted in mice to evaluate the pruritogenic and analgesic effects of BAM8-22. The peptide is administered intradermally or intrathecally, and scratching behavior is quantified. Analgesic effects are assessed using pain models such as the hot plate test or formalin test. The involvement of MRGPRs is confirmed using receptor antagonists or knockout mice.
|
| ADME/Pharmacokinetics |
BAM8-22 has a molecular formula of C91H127N25O23S and a molecular weight of 1971.22. The peptide sequence is Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly (RPEWWMDYQKRYG). It is soluble in water and should be stored at -20°C. The peptide is stable as a lyophilized powder and should be reconstituted in appropriate buffers for use.
|
| Toxicity/Toxicokinetics |
The toxicity profile of BAM8-22 is not well-documented in the literature. As an endogenous peptide fragment, it is expected to have a limited toxicity profile at physiological concentrations. At higher doses, it may induce itch and nociceptive sensations. Standard peptide toxicity studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
BAM8-22 belongs to the opioid peptide family and is used in neuroscience research to study pain modulation, stress responses, and opioid receptor signaling. It is also known as BAM(8-22), BAM-22P (8-22), and Bovine Adrenal Medulla Peptide (8-22). The peptide serves as a useful tool for investigating endogenous opioid peptide function and MRGPR signaling.
|
| Molecular Formula |
C91H127N25O23S
|
|---|---|
| Molecular Weight |
1971.229
|
| Exact Mass |
1969.93
|
| CAS # |
412961-36-5
|
| Related CAS # |
BAM(8-22) TFA
|
| PubChem CID |
16158367
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.471
|
| Hydrogen Bond Donor Count |
29
|
| Hydrogen Bond Acceptor Count |
28
|
| Rotatable Bond Count |
62
|
| Heavy Atom Count |
140
|
| Complexity |
4200
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC4=CNC5=CC=CC=C54)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC6=CC=C(C=C6)O)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC7=CC=C(C=C7)O)C(=O)NCC(=O)O)N
|
| InChi Key |
GOEYECACIBFJGZ-NPAGUKBMSA-N
|
| InChi Code |
InChI=1S/C91H127N25O23S/c1-48(2)76(94)88(138)103-46-72(120)105-64(19-11-36-100-91(97)98)89(139)116-37-12-20-70(116)87(137)110-62(30-32-73(121)122)81(131)113-68(42-52-45-102-58-16-7-5-14-56(52)58)85(135)114-67(41-51-44-101-57-15-6-4-13-55(51)57)84(134)109-63(33-38-140-3)82(132)115-69(43-74(123)124)86(136)112-66(40-50-23-27-54(118)28-24-50)83(133)108-61(29-31-71(93)119)80(130)106-59(17-8-9-34-92)78(128)107-60(18-10-35-99-90(95)96)79(129)111-65(77(127)104-47-75(125)126)39-49-21-25-53(117)26-22-49/h4-7,13-16,21-28,44-45,48,59-70,76,101-102,117-118H,8-12,17-20,29-43,46-47,92,94H2,1-3H3,(H2,93,119)(H,103,138)(H,104,127)(H,105,120)(H,106,130)(H,107,128)(H,108,133)(H,109,134)(H,110,137)(H,111,129)(H,112,136)(H,113,131)(H,114,135)(H,115,132)(H,121,122)(H,123,124)(H,125,126)(H4,95,96,99)(H4,97,98,100)/t59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,76-/m0/s1
|
| Chemical Name |
(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-6-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-(carboxymethylamino)-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-amino-3-methylbutanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid
|
| Synonyms |
BAM-8-22; BAM 8-22; BAM8-22
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~50.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (50.73 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5073 mL | 2.5365 mL | 5.0730 mL | |
| 5 mM | 0.1015 mL | 0.5073 mL | 1.0146 mL | |
| 10 mM | 0.0507 mL | 0.2536 mL | 0.5073 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
